Editas Medicine, Inc. Fair Value Disclosure
| Financial Assets | December 31, 2025 | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||||
| Cash equivalents: | ||||||||||||||||||||||||||
| Money market funds | $ | 146,645 | $ | 146,645 | $ | — | $ | — | ||||||||||||||||||
| Restricted cash and other non-current assets: | ||||||||||||||||||||||||||
| Money market funds | 2,670 | 2,670 | — | — | ||||||||||||||||||||||
| Total financial assets | $ | 149,315 | $ | 149,315 | $ | — | $ | — | ||||||||||||||||||
| Financial Assets | December 31, 2024 | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||||
| Cash equivalents: | ||||||||||||||||||||||||||
| Money market funds | $ | 131,541 | $ | 131,541 | $ | — | $ | — | ||||||||||||||||||
| Marketable securities: | ||||||||||||||||||||||||||
| Government agency securities | — | — | — | — | ||||||||||||||||||||||
| Corporate bonds | 6,501 | — | 6,501 | — | ||||||||||||||||||||||
| U.S. Treasuries | 131,871 | 131,871 | — | — | ||||||||||||||||||||||
| Restricted cash and other non-current assets: | ||||||||||||||||||||||||||
| Money market funds | 3,877 | 3,877 | — | — | ||||||||||||||||||||||
| Total financial assets | $ | 273,790 | $ | 267,289 | $ | 6,501 | $ | — | ||||||||||||||||||
Want the next Editas Medicine, Inc. fair value disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Editas Medicine, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 5, 2025 | |
| 2023 | Feb 28, 2024 | |
| 2022 | Feb 22, 2023 | |
| 2021 | Feb 24, 2022 | |
| 2020 | Feb 26, 2021 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.